- Home
- HAYW vs IMVT Comparison
HAYW vs IMVT Comparison
Compare HAYW & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- IMVT
- Stock Information
- Founded
- HAYW 1925
- IMVT 2018
- Country
- HAYW United States
- IMVT United States
- Employees
- HAYW N/A
- IMVT N/A
- Industry
- HAYW Electronic Components
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAYW Technology
- IMVT Health Care
- Exchange
- HAYW Nasdaq
- IMVT Nasdaq
- Market Cap
- HAYW 2.9B
- IMVT 2.7B
- IPO Year
- HAYW 2021
- IMVT N/A
- Fundamental
- Price
- HAYW $16.56
- IMVT $15.24
- Analyst Decision
- HAYW Hold
- IMVT Buy
- Analyst Count
- HAYW 5
- IMVT 11
- Target Price
- HAYW $16.83
- IMVT $35.88
- AVG Volume (30 Days)
- HAYW 3.0M
- IMVT 1.2M
- Earning Date
- HAYW 07-30-2025
- IMVT 08-11-2025
- Dividend Yield
- HAYW N/A
- IMVT N/A
- EPS Growth
- HAYW 46.31
- IMVT N/A
- EPS
- HAYW 0.60
- IMVT N/A
- Revenue
- HAYW $1,083,088,000.00
- IMVT N/A
- Revenue This Year
- HAYW $5.27
- IMVT N/A
- Revenue Next Year
- HAYW $5.42
- IMVT N/A
- P/E Ratio
- HAYW $27.61
- IMVT N/A
- Revenue Growth
- HAYW 8.77
- IMVT N/A
- 52 Week Low
- HAYW $11.10
- IMVT $12.72
- 52 Week High
- HAYW $16.87
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- HAYW 64.43
- IMVT 43.58
- Support Level
- HAYW $15.63
- IMVT $14.50
- Resistance Level
- HAYW $16.18
- IMVT $15.52
- Average True Range (ATR)
- HAYW 0.43
- IMVT 0.69
- MACD
- HAYW 0.02
- IMVT -0.06
- Stochastic Oscillator
- HAYW 88.82
- IMVT 41.16
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.